Michel E. Marty
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 01, 2019
La Société française du cancer strengthens its information and education activity
Journal: Bulletin du cancer
Published: February 13, 2018
La Société Française du Cancer is moving forward
Journal: Bulletin du cancer
Published: January 15, 2017
Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 22, 2016
BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.
Journal: Breast cancer research and treatment
Published: June 13, 2016
First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma.
Journal: British journal of cancer
Published: February 04, 2016
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 10, 2015
Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies.
Journal: Leukemia & lymphoma
Published: August 27, 2015
Last Updated: 09/26/2026